PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for VIJOICE, indicated for adults and children age 2 and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum.
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for ENSACOVE and exclusive hub services provider for adults with advanced ALK-positive non-small cell lung cancer.
VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for VORANIGO, the first targeted therapy developed specifically for patients with IDH-mutant diffuse glioma.
ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for ZOKINVY, the only FDA-approved treatment to reduce mortality risk in Hutchinson-Gilford Progeria Syndrome.
RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for RYTELO, a first-in-class telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes and transfusion-dependent anemia.
CAMCEVI® (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson
Biologics by McKesson became an exclusive specialty pharmacy provider for CAMCEVI, a subcutaneous leuprolide injection for adult patients with advanced prostate cancer.
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
Biologics by McKesson joined a limited network as a specialty pharmacy provider for OJEMDA, an oral RAF inhibitor for pediatric low-grade glioma.
FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for FABHALTA, the first oral monotherapy approved for adults with paroxysmal nocturnal hemoglobinuria.
OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for OGSIVEO, the first FDA-approved drug for adults with progressing desmoid tumors requiring systemic treatment.